US sales of Humalog in Q3 were nearly $415 million ... The FDA approved its short-acting insulin, Fiasp (insulin aspart injection) in September, and its long-acting insulin Tresiba (insulin ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Crucially, the long-acting insulin was no worse than Tresiba when it came to rates of hypoglycaemia, when blood glucose levels dip too low, according to statistical comparisons between the drugs.

Researchers have determined that in comparison to insulin treatment, the use of a strategy of oral glucose-lowering agents with metformin and glyburide for the management of gestational diabetes ...